

Optimal Pre-dilatation Treatment before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis. The OPTIMIS trial

Kirstine Nørregaard Hansen MD^{1,2}, Jens Trøan MD¹, Akiko Maehara MD³, Manijeh Noori MD^{1,2},
Mikkel Hougaard MD PhD¹, Julia Ellert-Gregersen MD PhD¹, Karsten Tange Veien MD¹, Anders
Junker MD PhD¹, Henrik Steen Hansen MD^{1,2}, Jens Flensted Lassen MD PhD^{1,2}, Lisette Okkels
Jensen MD DMSci PhD^{1,2}

¹Department of Cardiology, Odense University Hospital, Odense, Denmark

²University of Southern Denmark, Odense, Denmark

³Cardiovascular Research Foundation, New York Presbyterian Hospital, New York, USA

Short title: Bioresorbable scaffolds and lesion preparation

Word count: 4,805

Correspondence to:

Kirstine Nørregaard Hansen MD
Odense University Hospital
Department of Cardiology
Sdr. Boulevard 29
5000 Odense C
Denmark
E-mail: kirstinenoerregaard@live.dk
Phone: +45 6541 2690

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21 **Introduction:** Bioresorbable scaffolds (BRS) have been developed to overcome limitations related
22 to late stent failures of drug-eluting-stents, but previous studies have observed lumen reduction over
23 time after implantation of BRS. The aim of the study was to investigate if lesion preparation with a
24 scoring balloon compared to a standard non-compliant balloon minimizes lumen reduction after
25 implantation of a Magmaris BRS (MgBRS) assessed with optical coherence tomography (OCT) and
26 intravascular ultrasound (IVUS).

27 **Method:** Eighty-two patients with stable angina pectoris were included and randomized in a ratio
28 1:1 to lesion preparation with either a scoring balloon or a standard non-compliant balloon prior to
29 implantation of a MgBRS. The primary endpoint was minimal lumen area (MLA) 6 months after
30 MgBRS implantation.

31 **Results:** Following MgBRS implantation, MLA ($6.4 \pm 1.6 \text{ mm}^2$ vs. $6.3 \pm 1.5 \text{ mm}^2$, $p=0.65$), mean
32 scaffold area ($7.8 \pm 1.5 \text{ mm}^2$ vs. $7.5 \pm 1.7 \text{ mm}^2$, $p=0.37$), and mean lumen area ($8.0 \pm 1.6 \text{ mm}^2$ vs.
33 $7.7 \pm 2.1 \text{ mm}^2$, $p=0.41$) did not differ significantly in patients where the lesions were prepared with
34 scoring vs. standard non-compliant balloon respectively. Six-month angiographic follow-up with
35 OCT and IVUS was available in seventy-four patients. The primary endpoint, 6-months MLA, was
36 significantly larger in lesions prepared with a scoring balloon compared to a standard non-
37 compliant balloon ($4.7 \pm 1.4 \text{ mm}^2$ vs. $3.9 \pm 1.9 \text{ mm}^2$, $p=0.04$), whereas mean lumen area (7.2 ± 1.4
38 mm^3 vs. 6.8 ± 2.2 , $p=0.35$) did not differ significantly. IVUS findings showed no difference in
39 mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group ($16.8 \pm$
40 2.9 mm^2 vs. $17.0 \pm 3.6 \text{ mm}^2$, $p=0.62$), whereas mean vessel area ($17.1 \pm 4.4 \text{ mm}^2$ vs. 15.7 ± 4.9
41 mm^2 , $p<0.001$) was smaller in lesions prepared with a standard non-compliant balloon due to
42 negative remodeling.

43 **Conclusion:** Lesion preparation with a scoring balloon prior to implantation of a MgBRS resulted
44 in significantly larger MLA after 6 months due to less negative remodeling compared to lesion
45 preparation with a standard non-compliant balloon.

46 Registration: URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT04666584.

47

48 **Clinical perspectives:**

49 What is new?

- 50 - Intense lesion preparation with a scoring balloon prior to implantation of a magnesium-
51 based Magmaris bioresorbable scaffold results in less lumen reduction and malapposition
52 after 6 month compared to conventional lesion preparation with a non-compliant balloon in
53 patients with stable angina.
- 54 - Negative remodeling was seen in lesions treated with conventional lesion preparation,
55 whereas optimal lesion preparation with a scoring balloon caused in stable remodeling.

56

57 What are the Clinical Implications?

- 58 - Lesions preparation with a scoring balloon is safe and ensures better vascular healing and
59 vessel dynamics after implantation of a magnesium-based Magmaris bioresorbable scaffold.
- 60 - Optimal lesion preparation should be considered before implantation of magnesium-based
61 Magmaris bioresorbable scaffold.

Non-standard Abbreviations and Acronyms	
BRS	Bioresorbable scaffold
DAPT	Dual antiplatelet therapy
DES	Drug-eluting stents
EEM	External elastic membrane
IVUS	Intravascular ultrasound
MLA	Minimal lumen area
MgBRS	Magnesium-based Magmaris bioresorbable scaffold
NOAC	Novel oral anticoagulant
OCT	Optical coherence tomography
OPTIMIS	Optimal Pre-dilatation Treatment before Implantation of a Magmaris bioresorbable scaffold In coronary artery Stenosis
PCI	Percutaneous coronary intervention

63 **Introduction**

64 Bioresorbable scaffolds (BRS) were developed to provide temporary vessel support during the early
65 phases of coronary vessel healing, leaving the artery stent-free after degradation as an alternative to
66 drug-eluting stents (DES) during percutaneous coronary intervention (PCI)^{1, 2}. The potential
67 advantages of BRS were restored vasomotion and potential reduction in late stent failures. The
68 Absorb everolimus-eluting BRS (Abbott Vascular, Abbott Park, IL, USA) showed increased risk of
69 scaffold thrombosis and vessel shrinkage over time³ with significant minimal lumen area (MLA)
70 reduction after 6 months assessed with optical coherence tomography (OCT)⁴. It is hypothesized
71 that the mechanism behind lumen reduction is based on decreased radial strength in BRS compared
72 with bare-metal stents and risk of recoil and scaffold dismantling⁵. The construction of BRS
73 continued to develop, and different types are now available on the market. The magnesium-based
74 BRS (Magmaris, Biotronik, Bülach, Switzerland) (MgBRS) was later introduced with improved
75 radial strength, stronger backbone, change in drug-polymer coating and showed better efficacy
76 compared to the first BRSs⁶⁻⁹. Head-to-head comparison between newer generation DES and the
77 MgBRS is limited, but the anti-restenotic efficacy has not yet solved the scaffold failure^{5, 10}.
78 Optimal lesion preparation prior to implantation of a MgBRS appeared to facilitate optimal scaffold
79 sizing and better expansion post-procedure in complex lesions¹¹, but the effect of aggressive pre-
80 dilation on vessel and lumen changes over time is uncertain. Peri-procedural intravascular imaging
81 is recommended during implantation of a MgBRS due to lack of a radiolucent backbone. OCT is
82 ideal to assess lumen contours¹², whereas intravascular ultrasound (IVUS) provides information on
83 the vessel wall and vessel remodeling over time^{13, 14}. The aim of this study was to assess whether a
84 more aggressive lesion preparation with a scoring balloon compared to a standard non-compliant
85 balloon prior to implantation of a MgBRS resulted in less lumen reduction MLA after 6 months.

86

87 **Methods**

88 *Study design*

89 The OPTIMIS (Optimal pre-dilatation Treatment before Implantation of a Magmaris bioresorbable
90 scaffold In coronary artery Stenosis) study was a prospective, randomized-controlled trial
91 conducted at Odense University Hospital in Denmark from December 2020 to September 2023. The
92 study compared lesion preparation with a scoring balloon to a standard non-compliant balloon, prior
93 to implantation of a MgBRS and the effect on lumen dimension in the scaffold treated segment after
94 6 months. The patients were randomized to the two pre-dilatation methods in a ratio 1:1. The
95 primary hypothesis of the OPTIMIS-study was that intense lesion preparation with a scoring
96 balloon prior to implantation for a MgBRS would result in a larger MLA after 6-month follow-up,
97 compared to standard pre-dilatation with a non-compliant balloon. A detailed description of the
98 study design has previously been published¹⁵.

99 The study was approved by the Regional Committees on Health Research Ethics for Southern
100 Denmark (Project-ID: S-20200114) and Danish Data Agency (Journal no.: 20/49900), the trial was
101 registered at ClinicalTrials.gov (NCT04666584).

102

103 *Patient population*

104 Eighty-two patients with stable angina pectoris referred to PCI were enrolled in the study, if they
105 met the inclusion criteria. Patients were eligible if; 1) age was between 18 and 80 years, 2) if they
106 had stable angina pectoris, 3) the target lesion was in a native coronary artery, 4) vessel was suitable
107 for treatment with MgBRS complying with the scaffolds recommended limitations of coronary
108 artery diameter between ≥ 2.75 mm and ≤ 4.0 mm measured with OCT or IVUS. Exclusion criteria
109 were 1) patients participating in other randomized stent studies, 2) expected survival < 1 year, 3)
110 allergy to aspirin, ticagrelor, clopidogrel or prasugrel, 4) allergy to sirolimus, 4) ostial lesions
111 (cannot be cleared with flush by OCT), 5) serum creatinine > 150 $\mu\text{g/L}$ (due to the required amount

of contrast by OCT), 6) vastly calcified (evaluated with OCT defined as an arc $> 180^\circ$, calcium thickness > 0.5 mm and calcium length of > 5 mm), 7) tortuous coronary arteries where the PCI-operator estimated that the introduction of an OCT-catheter would not be possible or would be associated with increased risk, and/or, 8) lesion length > 40 mm. All patients were screened for protocol inclusion and exclusion criteria before enrolment. Patients underwent clinical and invasive imaging follow-up with OCT and IVUS at 6 months.

Antithrombotic therapy

Patients were treated with aspirin 75 mg /day prior to the PCI procedure. On the day for the PCI, they received a loading dose of 600 mg clopidogrel. Patients were prescribed dual antiplatelet therapy (DAPT) with aspirin 75 mg /day and clopidogrel 75 mg/day for 6 months followed by lifelong monotherapy with 75 mg of aspirin. Patients in Warfarin or novel oral anticoagulant (NOAC) were loaded with 600 mg of clopidogrel. If patients had been admitted and treated for an acute myocardial infarction within the last 12 months, patients kept their previously prescript antithrombotic medication.

Devices

The metallic-based MgBRS contains a magnesium alloy with a bioresorbable poly-L-lactide acid polymer coated with sirolimus as eluting drug released completely after 100 days. The strut thickness is 150 μm . The MgBRS is completely absorbed after 1 year¹⁶. The scaffold sizes were available in a diameter of 3.0 mm and 3.5 mm, and lengths of 15, 20, and 25 mm.

The scoring balloon (ScoreFlex, OrbusNeich) catheter is a short mono-rail type balloon catheter. It provides forced dilatation with a dual-wire semi-compliant balloon system which facilitates local, safe and controlled plaque modification at lower resolution pressure.

136

137 *Procedure strategy*

138 The coronary stenosis was identified by the PCI operator's interpretation of the angiography and
 139 was treated with a MgBRS in all patients. Patients received a dose of heparin (70 UI/kg) prior to the
 140 procedure. At the discretion of the operator, pre-dilatation with a 2.0 mm balloon was allowed. Pre-
 141 interventional imaging with OCT and IVUS was performed. The scaffold sizing was based on the
 142 external elastic membrane (EEM) diameters of the proximal and distal reference segments. If the
 143 EEM was visible in $>180^\circ$ of the cross sectional area, the smaller EEM diameter rounded down to
 144 the nearest 0.5 mm was used to determine scaffold diameter. If the EEM was visible in $<180^\circ$, the
 145 scaffold diameter was based on the lumen diameter¹⁷. Patients were allocated 1:1 to either lesion
 146 preparation with 1) a scoring balloon, or 2) a standard non-compliant balloon. The lesion was pre-
 147 dilated in a 1:1 balloon:artery ratio. Up-scaling to a 0.5 mm larger balloon was allowed, if the pre-
 148 dilatation goal was not achieved, as long as the balloon type corresponded to the randomization
 149 arm. The pre-dilatation goal was an angiographic residual stenosis of less than 20%. The lesion was
 150 then treated with implantation of a MgBRS, and inflation pressure was maintained for 30 seconds
 151 during implantation. Mandatory post-dilatation was performed with a non-compliant balloon with
 152 the same size or maximally 0.5 mm larger than the implanted scaffold. Lastly, intravascular
 153 imaging with OCT and IVUS of the scaffold treated segment was performed and controlled by the
 154 PCI-operator and an on-site OCT-analyst. Optimization (if any) was performed at the operators'
 155 discretion. Additional intervention was allowed if there was 1) major under-expansion (minimal
 156 scaffold area (MSA) $< 4.5 \text{ mm}^2$), 2) major malapposition (defined as strut $> 0.3 \text{ mm}$ from the lumen
 157 wall for $> 3 \text{ mm}$), 3) presence of significant edge dissection, or 4) residual stenosis $< 5 \text{ mm}$ proximal
 158 or distal to the scaffold (causing MLA $< 4 \text{ mm}^2$). Repeated OCT and IVUS of the final result were

then performed. Blinding of the patient, PCI-operator or investigator to pre-dilatation technique was not possible during the index procedure.

Intravascular imaging acquisition

OCT and IVUS were performed at baseline and after 6-month of follow-up. The imaging procedures were preceded by administration of 200 µg of intracoronary nitroglycerin. OCT was performed with frequency-domain OPTIS OCT system (Illumien OCT system; Abbott Vascular, Santa Clara, CA, USA) using the Dragonfly™ Imaging catheter. The catheter was positioned 10 mm distally to the lesion or scaffold-treated segment, and the coronary artery was then flushed with 15 ml contrast injection to clear the artery for blood during automated pullback at a rate of 20 mm/s over a distance of 75 mm. The IVUS system (Boston Scientific, Marlborough, MA, USA) used a 40MHz OptiCross 2.6 Fr catheter placed 10 mm distally to the lesion or scaffold-treated segment. Motorized IVUS pullbacks were performed with a pullback speed of 0.5 mm/sec after intracoronary bolus of 200 µg nitroglycerine.

Intravascular imaging analysis

The intravascular imaging pullbacks were analyzed by two independent analysts who were both blinded to the pre-dilatation technique during analysis. The baseline IVUS and OCT pullbacks were matched with the follow-up images using anatomical landmarks. OCT offline software (Offline Review Workstation; Abbott Vascular) was used for quantitative OCT analysis, and the commercially available program for computerized IVUS-analysis Echoplaque (INDEC Systems, Inc., Santa Clara, CA, USA) was used for IVUS-analysis. The scaffold-treated segment was analyzed for every mm. Lumen dimensions at baseline and follow-up were measured: MLA, mean lumen area, lumen volume, and difference in MLA (follow-up MLA – baseline MLA). Quantitative

analysis of scaffold was done using IVUS, because IVUS showed better detection of scaffold remnants than OCT. Scaffold dimensions at baseline were measured: MSA, mean scaffold area, minimum scaffold diameter, and scaffold volume. Scaffold malapposition was defined to be present when the distance between the abluminal surface of the strut and the luminal surface of the vessel wall exceeded the struts thickness of 150 μm . Major malapposition was defined as struts $> 0.3 \text{ mm}$ from the lumen wall for $>3 \text{ mm}$ in length¹⁸, and the remaining were classified as minor. At baseline, malapposition area, distance, and volume were analyzed. At follow-up, visible struts or strut remnants were categorized as malapposed when the abluminal border of the strut/remnant was separated from the lumen surface by a visible space exceeding 150 μm . The malapposition observations was matched from baseline to follow-up and divided into resolved, persistent, or late acquired malapposition. If a scaffold contained both resolved and persistent malapposition at follow-up, it was summarized as persistent. To evaluate the effect of pre-dilatation method on remodeling in the specific lesion site, IVUS was used to identify the pre-procedure MLA in lesion. The lesion site was defined as 5 mm proximally and distally to MLA. The corresponding 10 mm segment was identified in IVUS pullback post-procedure and at 6-month follow-up using anatomical landmarks such as side branches, calcified plaques and scaffold edges. Remodeling was defined as changes in mean EEM area in the lesion site and deemed significant if the mean EEM area changed more than 0.5 mm^2 . Enlargement was defined as positive remodeling, and reduction in mean EEM area was defined as negative remodeling. Quantitative IVUS analysis included measurements of EEM, peri-scaffold plaque (EEM area – scaffold area), and total plaque area (EEM area – lumen area).

Statistical analysis

Categorical data was presented as numbers and frequencies and compared using chi-square test or Fisher's exact statistics. Continuous data was presented as mean \pm SD and compared using Student's t-test. Paired t-test was used for comparison from baseline to follow-up. If the distribution were skewed, a non-parametric test was performed, and median with interquartile range (IQR) was stated.

All tests were two-tailed, and a p-value <0.05 was considered statistically significant. STATA version 18.0 (StataCorp, Collage Station, TX, USA) was used for the statistical analysis. Inter-observer variability for imaging analysis was tested for consistency of agreement using an intraclass correlation coefficient (ICC) was calculated for MLA at follow-up and for malapposition area at baseline and follow-up. The Pearson correlation coefficient was used to evaluate the direction and strength of the linear relation between two parameters.

The estimated sample size was based on data from the HONEST study¹⁹. The reduction of MLA from 6.99 mm² to 5.01 mm² (27%) 6 months after implantation of the Magmaris BVS, represented the expected reference group. Optimal lesion preparation with pre-dilatation with a scoring balloon is estimated to minimize MLA reduction from 6.99 mm² to 6.22 mm² (11%). A power calculation is conducted using the expected MLA after 6 months (6.22 mm² for the scoring balloon and 5.01 mm² for the standard non-compliant balloon). Inclusion of 35 patients in each group is necessary to reach statistical significance in case of 2-tailed significance level of 0.05 and power of 80 %. Loss to follow-up and poor image quality finalize an expected drop-out rate of 15 %, thereby requiring 82 patients in total.

Endpoints

The primary endpoint was MLA in the scaffold-treated segment pre-dilated with a scoring balloon versus standard non-compliant balloon 6-month after implantation of a MgBRS assessed with OCT.

Secondary endpoints were differences between treatment groups in: 1) change in MLA, and 2) percentage and size of incomplete scaffold apposition at baseline and follow-up.

Results

A flowchart of enrolled patients is provided in Figure 1.

In total, 82 patients were enrolled in the study. Follow-up images were not available in 8 patients due to following reasons. One patient randomized to standard non-compliant balloon pre-dilatation was excluded due to vessel dissection that could not be covered by a MgBRS scaffold. Two patients were excluded, one in the scoring balloon group and one in the standard non-compliant balloon group, due to scaffold failure where the MgBRS was lost in the coronary artery proximally to the study lesion. In all three cases, patients were treated with a DES. Five patients had unavailable follow-up images: Two patients withdrew consents (one in the scoring balloon group and one standard non-compliant balloon group), one patient died within the 6-month angiographic follow-up (standard non-compliant balloon group), one patient had a subacute scaffold thrombosis 5 days after implantation (standard non-compliant balloon group), and one patient was postponed due to nurses' strike (standard non-compliant balloon group).

Clinical and procedural characteristics

Baseline clinical and procedural characteristics are presented in Table 1 and Table 2.

The treatment groups were well matched without any significant differences in baseline characteristics. Also, there were no significant differences in procedural characteristics, except for balloon length which was significantly shorter in the scoring balloon group (only available in 10 and 15 mm) (13.1 ± 2.5 mm vs. 15.5 ± 3.3 mm, $p < 0.001$) compared to the standard non-compliant balloon group.

254

255 *Optical coherence tomography findings*

256 Post-procedure and 6-month follow-up OCT findings are presented in Table 3. Inter-observer
257 variability for MLA at follow-up was: ICC=0.996 (95% confidence interval (CI): 0.999-1.00,
258 $p<0.001$), for total malapposition area at baseline: ICC=0.949 (95% CI: 0.77-0.99, $p<0.001$), and
259 for total malapposition at follow-up: ICC=0.874 (95% CI: 0.50-0.97, $p=0.001$).

260

261 Lumen dimensions

262 At baseline, there was no significant difference in MLA, mean LA, or lumen volume between the
263 two treatment groups assessed with OCT. At 6-month follow-up, MLA (the primary endpoint) in
264 the scaffold-treated segment was significantly larger in the patients allocated to pre-dilatation with a
265 scoring balloon, compared to a standard non-compliant balloon ($4.71 \text{ mm}^2 \pm 1.35$ vs. $3.91 \text{ mm}^2 \pm$
266 1.86 , $p = 0.04$). There was no significant difference between the two groups in mean LA, or lumen
267 volume at 6-month follow-up. There was a relative reduction in MLA of -24.8% for the scoring
268 balloon group compared to -38.3% in the standard non-compliant balloon group, $p=0.009$.
269 Representative cases of lumen reduction from baseline to follow-up are shown in Figure 2.

270

271 Scaffold measurements and malapposition

272 At baseline, scaffold parameters, such as scaffold length, mean scaffold area, minimal scaffold area,
273 and total scaffold volume were similar in the two groups. Total number of analyzable struts were
274 similar at baseline between the two groups (199.9 ± 70.5 in the scoring balloon group and $210.7 \pm$
275 60.0 in the standard non-compliant balloon group, $p=0.46$). At follow-up, the total number of
276 analyzable struts were reduced to 70.8 ± 35.1 in the scoring balloon group and 85.1 ± 32.1 in the
277 standard non-compliant balloon group ($p=0.07$).

278 At baseline, half of the scaffolds in both groups had minor malapposition. There were no major
279 malappositions in any of the groups. Percentage of malapposed struts was small in both groups and
280 significantly lower in the scoring balloon group with 1.5 % compared to 4.6 % in the standard non-
281 compliant balloon group ($p=0.02$). At baseline, malapposition volume tended to be smaller in the
282 scoring balloon group (0.38 mm^2 [0.15 ; 0.95]) compared to the standard non-compliant balloon
283 group [1.07 mm^2 0.48 ; 2.27], but there was no significant difference ($p= 0.09$).

284 At 6-month follow-up, 15.4% of the lesions treated with the scoring balloon had minor
285 malappositions, whereas 42.9% in the standard balloon group had minor malappositions ($p=0.009$).
286 There significantly smaller total malapposition volume (0.0 [0.0 ; 0.0] vs. 0.21 [0.0 ; 0.59],
287 $p=0.009$) and percentage of malapposed struts (0.0 [0.0 ; 0.0] vs. 1.62 [0.0 ; 3.49], $p=0.004$) in the
288 scoring group compared to the standard non-compliant balloon group at 6-month follow-up. Type
289 of malapposition did not differ between groups. Malappositions were resolved in 31.4 % of the
290 scaffolds in the scoring balloon group, compared to 48.6% in the standard non-compliant balloon
291 group. In the scoring balloon group, 5% had persistent malapposition vs. 20% in the standard
292 balloon group. Late acquired malapposition was seen in 15.4% in the scoring balloon group
293 compared to 22.9% in the standard non-compliant balloon group, and often positioned at scaffold
294 edge and in relation to calcified plaque. Malapposition types are presented in Figure 3.

295 At 6-month follow-up, no scaffold area and volume were drawn since most of the struts were
296 absorbed. OCT images of scaffold degradation are shown in Figure 2. The total number of struts
297 were similar in the two groups, but there were significantly less struts per cross section in the
298 scoring balloon group compared to standard non-compliant balloon group after 6 months.

299

300 *Intravascular ultrasound findings*

301 Post-procedure and 6-month follow-up IVUS findings are presented in Table 3 and Table 4 and
302 Supplementary table 1.

303

304 Vessel dimensions

305 There was no difference in vessel measurements between the two groups at baseline or at 6-month
306 follow-up (Table 3). The paired analysis of mean area in the 10 mm lesion site and corresponding
307 segment post-procedure and at 6-month follow-up are presented in Table 4. There was no
308 significant difference in mean lumen area from post-procedure to 6-month follow-up in the scoring
309 balloon group ($8.5 \pm 1.4 \text{ mm}^2$ vs. $8.1 \pm 1.8 \text{ mm}^2$, $p=0.08$), whereas a significant decrease in lumen
310 area was found in the standard non-compliant balloon group ($8.2 \pm 1.7 \text{ mm}^2$ vs. $7.4 \pm 2.6 \text{ mm}^2$,
311 $p=0.009$). Vessel area in the 10 mm segment corresponding to the lesion site did not change in the
312 scoring balloon group from baseline to 6-month follow-up ($16.8 \pm 2.9 \text{ mm}^2$ vs. $17.0 \pm 3.6 \text{ mm}^2$,
313 $p=0.62$), but was significantly decreased ($17.1 \pm 4.4 \text{ mm}^2$ vs. $15.7 \pm 4.9 \text{ mm}^2$, $p < 0.001$) in the
314 standard non-compliant balloon group indicating negative remodeling.

315

316 Pattern of remodeling

317 Figure 4 shows the relationship between relative change in lumen area and relative change in vessel
318 area (A), and relative change in lumen area and relative change in plaque area (B). There was a
319 significant positive correlation between relative change in lumen area and relative change in vessel
320 area at the 10 mm lesion site ($r=0.72$, 95% CI: 0.58-0.81, $p<0.001$), but there was no correlation
321 between relative change in lumen area and relative change in plaque area ($r=-0.02$, 95% CI: -0.25-
322 0.21, $p=0.88$).

323

324 *Clinical 6-month follow-up*

325 In patients allocated to pre-dilatation with a scoring balloon prior to implantation of the MgBRS
326 one patient had a target vessel revascularization not related to the scaffold-treated segment. There
327 were no events observed corresponding to the scaffold-treated segment in the scoring balloon
328 group. In patients treated with the standard balloon prior to implantation of the MgBRS following
329 events were observed: one patient admitted with STEMI and subacute scaffold thrombosis 5 days
330 after index procedure. This patient was only treated with aspirin for 4 days followed by
331 monotherapy with clopidogrel as the patient also received NOAC; one patient died due to an
332 intracranial hemorrhage 92 days after index procedure.

333

334 **Discussion**

335 In summary, we found that MLA assessed with OCT was significantly larger in the scoring balloon
336 group compared to the standard non-compliant balloon group 6 month after implantation of the
337 MgBRS. In both groups, MLA decreased from baseline to 6-month follow-up, but less MLA
338 reduction was seen in the scoring balloon group compared to the standard non-compliant balloon
339 group. At the lesion site, there was no change in remodeling from baseline to follow-up in the
340 scoring balloon group, whereas negative remodeling was observed in lesions prepared with the
341 standard non-compliant balloon. In the lesions pre-dilated with a scoring balloon, there was
342 significantly less malapposition at follow-up compared to the standard non-compliant balloon
343 group.

344 The magnesium-based BRS was first evaluated in the DREAM 1G study²⁰, where a significant
345 decrease in MLA was observed within the first 6 months ($7.9 \text{ mm}^2 \pm 1.2$ vs. $5.7 \text{ mm}^2 \pm 1.0$) after
346 implantation assessed with OCT. The second generation magnesium-based BRS, MgBRS, had
347 higher flexibility and higher radial force, than the first generation magnesium-based BRS²¹.

348 Previous studies have investigated the vascular healing after 6 months of the magnesium-based
349 BRS with both IVUS and OCT, but significant lumen decrease continued to occur^{6, 19, 22, 23}.
350 Assessed with OCT, malapposition, neointimal hyperplasia and strut coverage were near impossible
351 to detect at follow-up, because the strut remnants had lost their metallic stent-like appearance
352 during the absorption process. Interestingly, the BIOSOLVE-II study (BIOTroniks – Safety and
353 performance in de novo Lesion of native coronary arteries with Magmaris) reported measurable
354 scaffold observation, such as mean and minimum scaffold area and incomplete strut apposition as
355 visible with IVUS, but not with OCT at 6-month follow-up²². The same pattern applied to our
356 findings, where scaffold area detection was not possible with OCT, but analyzable with IVUS at 6-
357 month follow-up. The BIOSOLVE-II trial²² measured smaller lumen and scaffold areas assessed
358 with IVUS compared to OCT, which was unlike our findings with smaller lumen and scaffold
359 measurements evaluated with OCT compared to IVUS. IVUS is often reported to overestimate
360 lumen area compared to OCT¹⁷, which may explain why no difference was found between the two
361 groups when using IVUS in lumen or scaffold measurements.

362 A third generation magnesium-based BRS (DREAMS-3G) has been developed with larger size
363 range, thinner struts (99/117/147 μm vs. 150 μm), and increased radial strength²⁴ compared to the
364 MgBRS used in our study. An absolute reduction in MLA was -2.4 mm^2 (from 7.2 mm^2 to 4.8 mm^2
365 at 6-month follow-up) for the DREAMS-3G, which was comparable to our results in the standard
366 non-compliant balloon group with an absolute reduction of -2.3 mm^2 . The scoring balloon group in
367 our study had less absolute reduction of -1.7 mm^2 . Even though, we found a significant difference
368 in MLA between the two groups, we still revealed lumen reduction in both groups from baseline to
369 6-month follow-up. Lumen reduction of 25% was considerably larger than the expected 11% lumen
370 reduction anticipated in our power calculation.

371 The HONEST trial²⁵ comparing OCT- and angio-guided implantation with the MgBRS in a
372 population with acute coronary syndrome found a significant reduction in MLA observed after 6
373 month in both groups with a relative difference of 33.2 % and 22.8 % in MLA, respectively. The
374 mechanism behind lumen reduction may be due to additional post-dilatation in an attempt to
375 optimize the apposition, resulting in fracture or dismantling of the scaffold hence reducing the
376 radial strength²⁶. Other mechanisms contributing to premature lumen loss after implantation of the
377 MgBRS could be scaffold recoil, neointimal hyperplasia and impact of underlying plaque
378 morphology and vessel remodeling⁵. The pattern of remodeling, with significant correlation
379 between change in lumen area and change in vessel area, but not between change in lumen area and
380 plaque area, indicated vessel reduction and not plaque increase as the overall reason for lumen
381 reduction. The pattern of remodeling was similar in the two groups, but the overall magnitude of
382 vessel reduction causing lumen reduction was larger in the standard non-compliant balloon group
383 compared the scoring balloon group. Our results reported significantly more decrease in vessel area
384 in lesions prepared with a standard non-compliant balloon, which was not seen in the lesions pre-
385 dilated with the scoring balloon. This indicates that negative remodeling and vessel shrinkage may
386 be contributing factors for lumen loss in our study in the standard non-compliant balloon group. In
387 the ABSORB Cohort B trial, dynamics of the vessel wall was investigated with IVUS after
388 implantation the everolimus-eluting bioresorbable ABSORB scaffold. They reported no evidence of
389 late recoil, but enlargement of the vessel, lumen and scaffold area up to three years after
390 implantation²⁷. The early resorption of the MgBRS with fast loss of radial force has been suggested
391 as a limiting factor to the device, and must be investigated further⁵. The extent of scaffold recoil is a
392 balance between elastic recoil and radial strength and can be affected by the fibrotic plaque in the
393 coronary artery in the treated segment⁵. Optimal pre-dilatation with a more aggressive lesion
394 preparation could result in a better vascular healing and less lumen reduction¹¹. More lipid-rich

395 plaques have been associated with less lumen loss after implantation of the MgBRS, whereas the
396 constrictive vascular forces and rigidity of fibrotic plaque may facilitate lumen reduction⁵. Patients
397 with acute coronary syndrome tend to have lesions with more lipid-rich plaque and positive
398 remodeling compared to our population of patients with stable coronary syndrome, which could
399 explain more lumen reduction than expected in the current study.

400 Percentage of post-procedure malapposed struts was small in our study in both groups (1.46% for
401 scoring balloon group and 4.57% for the standard non-compliant balloon group). As shown in
402 previous trials^{5, 19, 20, 22}, most struts will not be visible after 6 months, due to the fast scaffold
403 absorption. Even though we found up to 43% of the scaffolds with malapposition had follow-up, the
404 percentage of malapposed struts and malapposition volume was low. Significantly less
405 malapposition was present in the scoring balloon group compared to the standard non-compliant
406 balloon group, which contributes to the assumption of better vascular healing after lesion
407 preparation with a scoring balloon. To determine if these findings are a part of the natural healing
408 process needs longer follow-up time.

409 Despite reported lumen loss after implantation of the MgBRS in various intravascular imaging
410 studies^{19, 22}, the clinical performance is still deemed safe and efficient in several studies. Registries
411 have reported safety and efficacy with low 1-year TLF rates of 3.3-5.4% and stent thrombosis rates
412 of 0.5%, and TLF of 7.8% and scaffold thrombosis of 0.5% up to 24 months after implantation^{9, 28,}
413 ²⁹. A registry study found no difference in 24-month clinical outcomes between patients with acute
414 vs. stable coronary syndromes who were treated with a MgBRS³⁰. Only few studies have compared
415 the MgBRS to DES, for example the MAGSTEMI trial (MAGnesium-based bioresorbable scaffold
416 in ST-segment Elevation Myocardial Infarction) that showed a significantly higher TLF rate in the
417 MgBRS group after 1 year in a ST-segment elevation myocardial infarction population¹⁰. However,
418 a retrospective cohort reported similar 1-year clinical outcome comparing the MgBRS to a

419 biodegradable polymer DES in a non-ST-segment elevation myocardial infarction cohort³¹. More
420 randomized controlled trials with long-term follow-up are needed to fully illuminate the clinical
421 benefits or disadvantages between the new generation BRS and traditional DES.

422

423 **Limitations**

424 There are some potential limitations to this study. The study was not powered to correlate clinical
425 endpoints with OCT and IVUS findings. The study was conducted during the COVID-19 pandemic
426 and was furthermore challenged by nurse strike and delivery problems of OCT catheters, why the
427 inclusion period was unexpectedly prolonged. Also, the patient and lesion selections were
428 influenced by limited available scaffold sizes.

429

430 **Conclusion**

431 After 6 months, lesion preparation with a scoring balloon, compared to a standard non-compliant
432 balloon, prior to implantation of a MgBRS resulted in larger MLA, no remodeling and less
433 malapposition, whereas negative remodeling was seen in the standard non-compliant balloon group.

434

435 **Sources of funding**

436 The study is an investigator-initiated trial, and did not receive any financial support.

437

438 **Declaration of competing Interest**

439 KNH, MN, JT, COF, MH, KTV, JEG, AJ, AM, JFL, HSH have no conflict of interests. LOJ has
440 received research grants from Biotronik, OrbusNeich, Biosensors, and Terumo to her institution.

441

References

1. Azzi N, Shatila W. Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization. *Rev Cardiovasc Med.* 2021;22:137-145
2. Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. *Journal of the American College of Cardiology.* 2017;70:60-74
3. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: A systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. *Lancet (London, England).* 2017;390:760-772
4. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. *Circulation.* 2010;122:2301-2312
5. Ueki Y, Räber L, Otsuka T, Rai H, Losdat S, Windecker S, et al. Mechanism of drug-eluting absorbable metal scaffold restenosis: A serial optical coherence tomography study. *Circulation. Cardiovascular interventions.* 2020;13:e008657
6. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (dreams) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man biosolve-i trial. *Lancet (London, England).* 2013;381:836-844
7. Haude M, Ince H, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (dreams 2g) in patients with de novo coronary lesions: Three-year clinical results and angiographic findings of the biosolve-ii first-in-man trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2020;15:e1375-e1382
8. Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the biosolve-ii first-in-man trial at 5 years. *Cardiovascular revascularization medicine : including molecular interventions.* 2022;38:106-110
9. Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, et al. Biosolve-iv-registry: Safety and performance of the magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.* 2021;98:E1-e8
10. Sabaté M, Alfonso F, Cequier A, Romaní S, Bordes P, Serra A, et al. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with st-segment elevation myocardial infarction: The magstemi randomized clinical trial. *Circulation.* 2019;140:1904-1916
11. Miyazaki T, Latib A, Ruparel N, Kawamoto H, Sato K, Figini F, et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: A comparison with conventional balloon predilatation. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2016;11:e1580-1588
12. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. *Journal of the American College of Cardiology.* 2012;59:1058-1072
13. Mintz GS, Guagliumi G. Intravascular imaging in coronary artery disease. *Lancet (London, England).* 2017;390:793-809
14. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus). A report of the american college of cardiology

task force on clinical expert consensus documents. *Journal of the American College of Cardiology*. 2001;37:1478-1492

15. Hansen KN, Maehara A, Noori M, Trøan J, Fallesen CO, Hougaard M, et al. Optimal lesion preparation before implantation of a magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the optimis study. *Contemp Clin Trials Commun*. 2024;38:101260
16. Gutiérrez-Chico JL, Cortés C, Schincariol M, Limon U, Yalcinli M, Durán-Cortés MA, et al. Implantation of bioresorbable scaffolds under guidance of optical coherence tomography: Feasibility and pilot clinical results of a systematic protocol. *Cardiology journal*. 2018;25:443-458
17. Maehara A, Matsumura M, Ali ZA, Mintz GS, Stone GW. Ivus-guided versus oct-guided coronary stent implantation: A critical appraisal. *JACC. Cardiovascular imaging*. 2017;10:1487-1503
18. Shlofmitz E, Croce K, Bezerra H, Sheth T, Chehab B, West NEJ, et al. The mld max oct algorithm: An imaging-based workflow for percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions*. 2022;100:S7-S13
19. Fallesen CO, Antonsen L, Maehara A, Noori M, Hougaard M, Hansen KN, et al. Optical coherence tomography- versus angiography-guided magnesium bioresorbable scaffold implantation in nstemi patients. *Cardiovascular revascularization medicine : including molecular interventions*. 2022;40:101-110
20. Waksman R, Prati F, Bruining N, Haude M, Böse D, Kitabata H, et al. Serial observation of drug-eluting absorbable metal scaffold: Multi-imaging modality assessment. *Circulation. Cardiovascular interventions*. 2013;6:644-653
21. Waksman R, Zumstein P, Pritsch M, Wittchow E, Haude M, Lapointe-Corriveau C, et al. Second-generation magnesium scaffold magmaris: Device design and preclinical evaluation in a porcine coronary artery model. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2017;13:440-449
22. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (biosolve-ii): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet (London, England)*. 2016;387:31-39
23. Tovar Forero MN, van Zandvoort L, Masdjedi K, Diletti R, Wilschut J, de Jaegere PP, et al. Serial invasive imaging follow-up of the first clinical experience with the magmaris magnesium bioresorbable scaffold. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2020;95:226-231
24. Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter biomag-i first-in-human study. *EClinicalMedicine*. 2023;59:101940
25. Fallesen CO, Maehara A, Antonsen L, Nørregaard Hansen K, Noori M, Flensted Lassen J, et al. Coronary artery healing process after bioresorbable scaffold in patients with non-st-segment elevation myocardial infarction: Rationale, design, and methodology of the honest study. *Cardiology*. 2021:1-11
26. Barkholt T, Webber B, Holm NR, Ormiston JA. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2020;96:E674-e682
27. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2014;9:1271-1284
28. Galli S, Troiano S, Pallosi A, Rapetto C, Pisano F, Aprigliano G, et al. Sustained safety and efficacy of magnesium reabsorbable scaffold: 2-year follow-up analysis from first magmaris

- 546 multicenter italian registry. *Cardiovascular revascularization medicine : including molecular*
547 *interventions*. 2022;41:69-75
- 548 29. Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, et al. Safety and clinical
549 performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo
550 lesions in native coronary arteries: Pooled 12-month outcomes of biosolve-ii and biosolve-iii.
551 *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac*
552 *Angiography & Interventions*. 2018;92:E502-e511
- 553 30. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, et al. Comparison of acute versus
554 stable coronary syndrome in patients treated with the magmaris scaffold: Two-year results from the
555 magmaris multicenter italian registry. *Cardiovascular revascularization medicine : including*
556 *molecular interventions*. 2023;57:53-59
- 557 31. Rola P, Włodarczak A, Włodarczak S, Barycki M, Szudrowicz M, Łanocha M, et al. Magnesium
558 bioresorbable scaffold (brs) magmaris vs biodegradable polymer des ultimaster in nste-acs
559 population-12-month clinical outcome. *Journal of interventional cardiology*. 2022;2022:5223317

560

Table 1: Patient baseline characteristics		
	Scoring balloon	Standard balloon
	N = 41	N = 41
Age, years	64.9 ± 9.0	64.8 ± 7.9
Male, n (%)	27 (65.9)	28 (68.3)
Family history of IHD, n (%)	19 (46.3)	17 (41.5)
History of smoking, n (%)		
Current smoker	6 (14.6)	6 (14.6)
Previous smoker	21 (51.2)	11 (26.8)
Hypertension, n (%)	17 (41.5)	25 (61.0)
Hypercholesterolemia, n (%)	11 (26.8)	13 (31.7)
Diabetes mellitus, n (%)	4 (9.8)	8 (19.5)
Body mass index, kg/m ²	27.9 ± 9.7	27.9 ± 3.7
eGFR, ml/min	79.7 ± 12.5	82.1 ± 11.6
Previous myocardial infarction, n (%)	9 (22.0)	4 (9.8)
Previous PCI, n (%)	11 (26.8)	6 (14.6)
Previous CABG, n (%)	0 (0.0)	0 (0.0)
CABG = coronary bypass graft, eGFR = estimated glomerular filtration rate, IHD = ischemic heart disease, PCI = percutaneous coronary intervention. Data is shown as mean ± standard deviation.		

561

562

Table 2: Procedural and angiographic characteristics		
	Scoring balloon	Standard balloon
	N = 41	N = 41
Target coronary artery, n (%)		
Left anterior descending	23 (56.1)	24 (58.5)
Left circumflex	6 (14.6)	8 (19.5)
Right coronary artery	12 (29.3)	9 (22.0)
Lesion length, mm	23.9 ± 10.5	22.5 ± 5.4
Reference vessel diameter, mm	3.4 ± 0.3	3.4 ± 0.3
Pre-dilatation, n (%)	41 (100)	41 (100)
Balloon diameter at pre-dilatation, mm	3.3 ± 0.3	3.3 ± 0.3
Balloon length at pre-dilatation, mm	13.1 ± 2.5*	15.5 ± 3.3
Max balloon pressure at pre-dilatation, atm	13.1 ± 2.8	14.0 ± 2.7
Number of scaffolds per lesion, mm	1.1 ± 0.3	1.1 ± 0.2
Scaffold length, mm	19.4 ± 4.1	21.0 ± 3.9
Scaffold diameter, mm	3.3 ± 0.2	3.3 ± 0.3
Maximum balloon pressure, atm	11.9 ± 2.2	12.0 ± 2.4
Expected scaffold diameter, mm	3.4 ± 0.3	3.4 ± 0.3
Post-dilatation, n (%)	38 (93)	41 (100)
Balloon diameter at post-dilatation, mm	3.7 ± 0.3	3.7 ± 0.4
Balloon length at post-dilatation, mm	14.5 ± 3.6	15.7 ± 3.3
Max balloon pressure at post-dilatation, atm	13.0 ± 2.6	12.8 ± 2.4
Flouro time, minutes	12.3 ± 5.3	11.8 ± 5.2

Contrast volume, ml	108.0 ± 42.9	102.6 ± 43.8
Procedure time, minutes	49.9 ± 17.7	47.9 ± 18.4
* significantly shorter balloon length at pre-dilatation in the scoring balloon group (p-value < 0.001)		

Table 3: Post-procedure and 6-month follow-up optical coherence tomography findings and intravascular ultrasound						
	Baseline			6-month follow-up		
	Scoring balloon	Standard balloon	p-value	Scoring balloon	Standard balloon	p-value
OCT finding						
Number of patients	40	38		39	35	
Time to 6-month follow-up, days				185 [182 ; 234]	184 [182 ; 192]	0.29
Lumen measurement						
Minimal lumen area, mm ²	6.42 ± 1.55	6.27 ± 1.48	0.65	4.71 ± 1.35	3.91 ± 1.86	0.04
Difference in minimal lumen area (6 months - baseline), mm ²				-1.70 ± 1.49	-2.30 ± 1.42	0.08
Relative change in minimal lumen area (6 months - baseline), %				-24.8 ± 20.4	-38.3 ± 22.7	0.009
Mean lumen area, mm ²	8.01 ± 1.62	7.66 ± 2.12	0.41	7.21 ± 1.41	6.79 ± 2.21	0.35
Total lumen volume, mm ³	167.31 ± 50.82	169.47 ± 54.70	0.86	151.50 ± 53.94	139.93 ± 52.95	0.36
Difference in total lumen volume (6 months - baseline), mm ³				-16.99 ± 21.35	-25.35 ± 28.45	0.16
Relative change in total lumen volume (6 months - baseline), %				-10.5 ± 11.7	-15.0 ± 16.8	0.20

Scaffold measurement							
	Total number of analyzable struts	199.9 ± 70.5	210.7 ± 60.0	0.46	70.8 ± 35.1	85.1 ± 32.1	0.07
	Mean no. of struts per cross section	9.11 ± 0.71	9.11 ± 0.82	1.00	3.1 ± 1.3	3.9 ± 1.7	0.03
	Scaffold length, mm	20.8 [16.5 ; 24.1]	22.2 [19.2 ; 24.8]	0.51	20.4 [17.2 ; 24.0]	21.0 [17.2 ; 25.2]	0.69
	Minimal scaffold area, mm ²	6.40 ± 1.50	6.09 ± 1.51	0.36			
	Mean scaffold area, mm ²	7.77 ± 1.49	7.45 ± 1.69	0.37			
	Total scaffold volume, mm ³	161.81 ± 45.93	160.88 ± 52.44	0.93			
Scaffold malapposition							
	Scaffold malapposition, n (%)	20 (50.0)	21 (55.3)	0.64	6 (15.4)	15 (42.9)	0.009
	Total malapposition volume, mm ³	0.38 [0.15 ; 0.95]	1.07 [0.48 ; 2.27]	0.09	0.0 [0.0 ; 0.0]	0.21 [0.0 ; 0.59]	0.009
	Mean malapposition distance, mm	0.23 [0.21 ; 0.28]	0.30 [0.25 ; 0.34]	0.003	0.0 [0.0 ; 0.0]	0.18 [0.0 ; 0.4]	0.004
	Percentage of malapposed struts, %	1.5 [0.6 ; 3.0]	4.57 [1.7 ; 5.8]	0.02	0.0 [0.0 ; 0.0]	1.6 [0.0 ; 3.5]	0.004
Types of incomplete stent apposition							
	Resolved, n (%)				17 (48.6)	11 (31.4)	0.28
	Persistent, n (%)				2 (5.0)	7 (20.0)	0.05
	Late acquired, n (%)				4 (10.3)	8 (22.9)	0.14

Intravascular ultrasound							
Number of patients		40	38		39	34	
Time to 6-month follow-up, days					183 [153 ; 290]	183.5 [134 ; 225]	0.66
Vessel measurements							
	EEM area at MLA site, mm ²	14.73 ± 3.39	16.19 ± 4.87	0.13	13.53 ± 3.50	13.70 ± 4.69	0.86
	Mean EEM area, mm ²	16.70 ± 2.87	16.96 ± 4.22	0.75	16.24 ± 3.23	15.59 ± 4.66	0.50
	Total EEM volume, mm ³	361.61 ± 97.49	383.88 ± 130.23	0.40	353.91 ± 120.67	336.85 ± 110.95	0.53

563


564

Table 4: Remodeling of lesion segment pre-procedure and corresponding segment post-procedure and at 6-month follow-up assessed with IVUS			
	Scoring N = 39	Standard N = 34	p-value
Mean lumen (mm ²)			
Pre-procedure	5.3 ± 1.4	4.8 ± 1.5	0.13
Post-procedure	8.5 ± 1.4	8.2 ± 1.7	0.31
6-month follow-up	8.1 ± 1.8	7.4 ± 2.6	0.19
Change (6 months – baseline)	-0.4 ± 1.5	-0.8 ± 1.6	0.41
p-value (baseline vs. 6 months)*	0.08	0.009	
Mean EEM area (mm ²)			
Pre-procedure	13.3 ± 3.1	13.4 ± 4.8	0.88
Post-procedure	16.8 ± 2.9	17.1 ± 4.4	0.74
6-month follow-up	17.0 ± 3.6	15.7 ± 4.9	0.20
Change (6 months – baseline)	0.2 ± 2.0	-1.4 ± 2.0	0.001
p-value (baseline vs. 6 months)*	0.62	< 0.001	
Mean plaque area (mm ²)			
Pre-procedure	7.9 ± 2.5	8.6 ± 3.9	0.39
Post-procedure	8.3 ± 2.0	8.9 ± 3.5	0.31
6-month follow-up	8.9 ± 2.4	8.3 ± 3.0	0.36
Change (6 months – baseline)	0.6 ± 1.3	-0.7 ± 1.9	0.002
p-value (baseline vs. 6 months)*	0.007	0.06	
Mean scaffold area (mm ²)			

	Post-procedure	9.5 ± 1.7	9.1 ± 1.9	0.26
	6-month follow-up	10.1 ± 2.1	8.9 ± 2.8	0.04
	Change (6 months – baseline)	0.6 ± 1.9	-0.2 ± 1.8	0.10
	p-value (baseline vs. 6 months)*	0.07	0.58	
*paired analysis				


565 **Figures and legends**

566 **Figure 1: Flow chart**



567

568 Figure 2: Intravascular images of lumen reduction after implantation of Magmaris bioresorbable scaffold.




569 The upper panel shows OCT images of minimal lumen area from baseline and the corresponding site at follow-up. The lower panel shows
 570 the matching site acquired with IVUS. Images A and B represent the vascular healing after lesion preparation with a scoring balloon prior
 571 to MgBRS implantation. Lumen area at baseline was 7.3 mm^2 measured with OCT and 7.5 mm^2 with IVUS. Vessel area was 12.7 mm^2 at
 572

573 baseline (A). At 6-month follow-up, lumen area was 8.8 mm² with OCT and 8.8 mm² with IVUS. Vessel area was 16.0 mm² (B). Images C
574 and D represent the vascular healing after implantation of a MgBRS in a lesion pre-dilated with a standard non-compliant balloon. Lumen
575 area at baseline was 8.8 mm² with OCT and 8.8 mm² with IVUS. Vessel area was 16.0 mm² (C). After 6 months, the matching site was
576 reduced to 5.1 mm² measured with OCT, and 5.6 mm² with IVUS. Vessel area was 13.8 mm² (D). Abbreviations: IVUS = Intravascular
577 ultrasound; MgBRS = Magmaris bioresorbable scaffold; OCT = Optical coherence tomography.

578


579 Figure 3: Optical coherence tomography images of malapposition types




580


581 Upper panel represents baseline optical coherence tomography images, and lower panel represents
582 6-month follow-up. A) There are three malapposed struts from 3 to 5 o'clock, and one malapposed
583 strut at 10 o'clock. The corresponding site after 6 months (B) revealed resolved malapposition from
584 3 to 5 o'clock, but persistent malapposition at 10 o'clock. C) Four malapposed struts are visible at
585 baseline from 5 to 7 o'clock. At 6-month follow-up, persistent malapposition is seen in the
586 corresponding cross section (D). E) All struts are well-apposed, but after 6 month acquired
587 malapposition appears at 7 to 8 o'clock.


Figure 4: Pattern of remodeling at the lesion site




A. Correlation between relative change in lumen area (%) and relative change in vessel area (%) at the lesion site. B. Correlation between relative change in lumen area (%) and relative change in plaque area at the lesion site







A**B**